Repros Therapeutics (NASDAQ: RPRX) and Anacor Pharmaceuticals (NASDAQ:ANAC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Earnings & Valuation

This table compares Repros Therapeutics and Anacor Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Repros Therapeutics $50,000.00 340.22 -$17.27 million ($0.50) -0.86
Anacor Pharmaceuticals N/A N/A N/A ($1.45) -68.32

Anacor Pharmaceuticals has lower revenue, but higher earnings than Repros Therapeutics. Anacor Pharmaceuticals is trading at a lower price-to-earnings ratio than Repros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

13.6% of Repros Therapeutics shares are owned by institutional investors. 2.5% of Repros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Repros Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Anacor Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.


This table compares Repros Therapeutics and Anacor Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repros Therapeutics -4,242.73% -894.22% -230.71%
Anacor Pharmaceuticals -92.08% -133.71% -38.09%

Analyst Ratings

This is a breakdown of current ratings and target prices for Repros Therapeutics and Anacor Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repros Therapeutics 0 1 0 0 2.00
Anacor Pharmaceuticals 0 0 0 0 N/A

Repros Therapeutics presently has a consensus price target of $0.39, indicating a potential downside of 9.30%. Given Repros Therapeutics’ higher possible upside, equities research analysts plainly believe Repros Therapeutics is more favorable than Anacor Pharmaceuticals.


Repros Therapeutics beats Anacor Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Repros Therapeutics

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

About Anacor Pharmaceuticals

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.